NCT05077267View on ClinicalTrials.gov

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

197

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

February 2, 2022

Study Completion Date

October 31, 2023

Conditions

COVID-19 Disease

Interventions

BIOLOGICAL

ABNCoV2 100ug

IM injection 100ug dose

BIOLOGICAL

ABNCoV2 50ug

IM injection 50ug dose

Trial Locations (2)

10629

Emovis GmbH, Berlin

22143

Velocity Clinical Research Hamburg, Hamburg

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT05077267 - ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects | Biotech Hunter | Biotech Hunter